Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis

References

1. 1.↵
   1. Thompson AJ,
   2. Banwell BL,
   3. Barkhof F, et al

   . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73 doi:10.1016/S1474-4422(17)30470-2 pmid:29275977

   CrossRefPubMed
2. 2.↵
   1. Hyun JW,
   2. Kim W,
   3. Huh SY, et al

   . Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. Mult Scler 2019;25:1488–95 doi:10.1177/1352458518790702 pmid:30043667

   CrossRefPubMed
3. 3.↵
   1. Gobbin F,
   2. Zanoni M,
   3. Marangi A, et al

   . 2017 McDonald criteria for multiple sclerosis: earlier diagnosis with reduced specificity? Mult Scler Relat Disord 2019;29:23–25 doi:10.1016/j.msard.2019.01.008 pmid:30658260

   CrossRefPubMed
4. 4.↵
   1. Reichenbach JR,
   2. Venkatesan R,
   3. Schillinger DJ, et al

   . Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 1997;204:272–77 doi:10.1148/radiology.204.1.9205259 pmid:9205259

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Haacke EM,
   2. Xu Y,
   3. Cheng YC, et al

   . Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612–18 doi:10.1002/mrm.20198 pmid:15334582

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Haacke EM,
   2. Makki M,
   3. Ge Y, et al

   . Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009;29:537–44 doi:10.1002/jmri.21676 pmid:19243035

   CrossRefPubMed
7. 7.↵
   1. Dal-Bianco A,
   2. Grabner G,
   3. Kronnerwetter C, et al

   . Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol 2017;133:25–42 doi:10.1007/s00401-016-1636-z pmid:27796537

   CrossRefPubMed
8. 8.↵
   1. Tallantyre E,
   2. Brookes M,
   3. Dixon J, et al

   . Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI. Neurology 2008;70:2076–78 doi:10.1212/01.wnl.0000313377.49555.2e pmid:18505982

   FREE Full Text
9. 9.
   1. Tallantyre EC,
   2. Morgan PS,
   3. Dixon JE, et al

   . A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions. Investigative Radiol 2009;44:491–94 doi:10.1097/RLI.0b013e3181b4c144 pmid:19652606

   CrossRefPubMed
10. 10.
    1. Mistry N,
    2. Abdel-Fahim R,
    3. Samaraweera A, et al

    . Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions. Mult Scler 2016;22:1289–96 doi:10.1177/1352458515616700 pmid:26658816

    CrossRefPubMed
11. 11.↵
    1. Sati P,
    2. Oh J,
    3. Constable RT, et al

    ; NAIMS Cooperative. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 2016;12:714–22 doi:10.1038/nrneurol.2016.166 pmid:27834394

    CrossRefPubMed
12. 12.
    1. Samaraweera AP,
    2. Clarke MA,
    3. Whitehead A, et al

    . The central vein sign in multiple sclerosis lesions is present irrespective of the T2* sequence at 3 T. J Neuroimaging 2017;27:114–21 doi:10.1111/jon.12367 pmid:27300318

    CrossRefPubMed
13. 13.↵
    1. Maggi P,
    2. Absinta M,
    3. Grammatico M, et al

    . The central vein sign differentiates MS from CNS inflammatory vasculopathies. Ann Neurol 2018;83:283–94 doi:10.1002/ana.25146 pmid:29328521

    CrossRefPubMed
14. 14.↵
    1. Tallantyre EC,
    2. Dixon JE,
    3. Donaldson I, et al

    . Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology 2011;76:534–39 doi:10.1212/WNL.0b013e31820b7630 pmid:21300968

    Abstract/FREE Full Text
15. 15.
    1. Campion T,
    2. Smith P,
    3. Turner B, et al

    . FLAIR* for the non-invasive histological diagnosis of multiple sclerosis (S29.003). Neurology 2015;84:(14 Suppl)S29.003
16. 16.↵
    1. Mistry N,
    2. Dixon J,
    3. Tallantyre E, et al

    . Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. JAMA Neurol 2013;70:623–28 doi:10.1001/jamaneurol.2013.1405 pmid:23529352

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Harrison DM,
    2. Li X,
    3. Liu H, et al

    . Lesion heterogeneity on high-field susceptibility MRI is associated with multiple sclerosis severity. AJNR Am J Neuroradiol 2016;37:1447–53 doi:10.3174/ajnr.A4726 pmid:26939635

    Abstract/FREE Full Text
18. 18.↵
    1. Chawla S,
    2. Kister I,
    3. Wuerfel J, et al

    . Iron and non-iron-related characteristics of multiple sclerosis and neuromyelitis optica lesions at 7T MRI. AJNR Am J Neuroradiol 2016;37:1223–30 doi:10.3174/ajnr.A4729 pmid:27012298

    Abstract/FREE Full Text
19. 19.↵
    1. Wuerfel J,
    2. Sinnecker T,
    3. Ringelstein EB, et al

    . Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult Scler 2012;18:1592–99 doi:10.1177/1352458512441270 pmid:22711711

    CrossRefPubMed
20. 20.↵
    1. Hosseini Z,
    2. Matusinec J,
    3. Rudko DA, et al

    . Morphology-specific discrimination between MS white matter lesions and benign white matter hyperintensities using ultra-high-field MRI. AJNR Am J Neuroradiol 2018;39:1473–79 doi:10.3174/ajnr.A5705 pmid:29930096

    Abstract/FREE Full Text
21. 21.↵
    1. Tintore M,
    2. Rovira A,
    3. Rio J, et al

    . Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015;138:1863–74 doi:10.1093/brain/awv105 pmid:25902415

    CrossRefPubMed
22. 22.↵
    1. Arrambide G,
    2. Tintore M,
    3. Espejo C, et al

    . The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain 2018;141:1075–84 doi:10.1093/brain/awy006 pmid:29462277

    CrossRefPubMed
23. 23.↵
    1. Sinnecker T,
    2. Clarke MA,
    3. Meier D, et al

    ; for the MAGNIMS Study Group. Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis. JAMA Neurol 2019 Aug 19. [Epub ahead of print] doi:10.1001/jamaneurol.2019.2478 pmid:31424490

    CrossRefPubMed
24. 24.↵
    1. Freedman MS,
    2. Thompson EJ,
    3. Deisenhammer F, et al

    . Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865–70 doi:10.1001/archneur.62.6.865 pmid:15956157

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Fedorov A,
    2. Beichel R,
    3. Kalpathy-Cramer J, et al

    . 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 2012;30:1323–41 doi:10.1016/j.mri.2012.05.001 pmid:22770690

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Hagemeier J,
    2. Heininen-Brown M,
    3. Poloni GU, et al

    . Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J Magn Reson Imaging 2012;36:73–83 doi:10.1002/jmri.23603 pmid:22407571

    CrossRefPubMed
27. 27.↵
    1. Poser CM,
    2. Paty DW,
    3. Scheinberg L, et al

    . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31 doi:10.1002/ana.410130302 pmid:6847134

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Campion T,
    2. Smith RJ,
    3. Altmann DR, et al

    . FLAIR* to visualize veins in white matter lesions: a new tool for the diagnosis of multiple sclerosis? Eur Radiol 2017;27:4257–63 doi:10.1007/s00330-017-4822-z pmid:28409356

    CrossRefPubMed
29. 29.↵
    1. Guo BJ,
    2. Yang ZL,
    3. Zhang LJ

    . Gadolinium deposition in brain: current scientific evidence and future perspectives. Front Mol Neurosci 2018;11:335–35 doi:10.3389/fnmol.2018.00335 pmid:30294259

    CrossRefPubMed
30. 30.↵
    1. Solomon AJ,
    2. Watts R,
    3. Ontaneda D, et al

    . Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm. Mult Scler 2018;24:750–57 doi:10.1177/1352458517726383 pmid:28820013

    CrossRefPubMed
31. 31.↵
    1. Kau T,
    2. Taschwer M,
    3. Deutschmann H, et al

    . The “central vein sign”: is there a place for susceptibility weighted imaging in possible multiple sclerosis? Eur Radiol 2013;23:1956–62 doi:10.1007/s00330-013-2791-4 pmid:23436147

    CrossRefPubMed
32. 32.↵
    1. Absinta M,
    2. Sati P,
    3. Gaitan MI, et al

    . Seven-Tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol 2013;74:669–78 doi:10.1002/ana.23959 pmid:23813441

    CrossRefPubMed
33. 33.↵
    1. Yao B,
    2. Bagnato F,
    3. Matsuura E, et al

    . Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 2012;262:206–15 doi:10.1148/radiol.11110601 pmid:22084205

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Bagnato F,
    2. Hametner S,
    3. Yao B, et al

    . Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134:3602–15 doi:10.1093/brain/awr278 pmid:22171355

    CrossRefPubMed
35. 35.↵
    1. Bian W,
    2. Harter K,
    3. Hammond-Rosenbluth KE, et al

    . A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler 2013;19:69–75 doi:10.1177/1352458512447870 pmid:22641301

    CrossRefPubMed
36. 36.↵
    1. Hammond KE,
    2. Metcalf M,
    3. Carvajal L, et al

    . Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–13 doi:10.1002/ana.21582 pmid:19107998

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Absinta M,
    2. Sati P,
    3. Fechner A, et al

    . Identification of chronic active multiple sclerosis lesions on 3T MRI. AJNR Am J Neuroradiol 2018;39:1233–38 doi:10.3174/ajnr.A5660 pmid:29724768

    Abstract/FREE Full Text
38. 38.↵
    1. Hametner S,
    2. Wimmer I,
    3. Haider L, et al

    . Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848–61 doi:10.1002/ana.23974 pmid:23868451

    CrossRefPubMed
39. 39.↵
    1. Engelborghs S,
    2. Niemantsverdriet E,
    3. Struyfs H, et al

    . Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst) 2017;8:111–26 doi:10.1016/j.dadm.2017.04.007 pmid:28603768

    CrossRefPubMed
40. 40.↵
    1. Clarke MA,
    2. Samaraweera AP,
    3. Falah Y, et al

    . Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: a prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty. Mult Scler 2020;26:433–41 doi:10.1177/1352458519882282

    CrossRef
41. 41.↵
    1. Maggi P,
    2. Absinta M,
    3. Sati P, et al

    . The “central vein sign” in patients with diagnostic “red flags” for multiple sclerosis: a prospective multicenter 3T study. Mult Scler 2020;26:421–32 doi:10.1177/1352458519876031 pmid:31536435

    CrossRefPubMed